{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:23:50Z","timestamp":1784165030927,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01341-6","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:00:24Z","timestamp":1756454424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-1943","authenticated-orcid":false,"given":"Christine E.","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswin","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rawstron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-8917","authenticated-orcid":false,"given":"Julia","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-5195","authenticated-orcid":false,"given":"I\u00f1aki","family":"Martin-Subero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Alcoceba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinis P.","family":"Calado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-7230","authenticated-orcid":false,"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-3220","authenticated-orcid":false,"given":"Anton W.","family":"Langerak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-3125","authenticated-orcid":false,"given":"Hendrik","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Langerbeins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Roulland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8529-640X","authenticated-orcid":false,"given":"Kostas","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-4712","authenticated-orcid":false,"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tait","family":"Shanafelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5044","authenticated-orcid":false,"given":"Jessica","family":"Okosun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2003","authenticated-orcid":false,"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"1341_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","volume":"130","author":"GE Marti","year":"2005","unstructured":"Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005;130:325\u201332.","journal-title":"Br J Haematol"},{"key":"1341_CR2","first-page":"S19","volume":"78","author":"AC Rawstron","year":"2010","unstructured":"Rawstron AC, Shanafelt T, Lanasa MC, Landgren O, Hanson C, Orfao A, et al. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytom B Clin Cytom 2010;78:S19\u201323.","journal-title":"Cytom B Clin Cytom"},{"key":"1341_CR3","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1182\/blood.2020006322","volume":"137","author":"SL Slager","year":"2021","unstructured":"Slager SL, Lanasa MC, Marti GE, Achenbach SJ, Camp NJ, Abbasi F, et al. Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood 2021;137:2046\u201356.","journal-title":"Blood"},{"key":"1341_CR4","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1182\/blood.2022016279","volume":"140","author":"SL Slager","year":"2022","unstructured":"Slager SL, Parikh SA, Achenbach SJ, Norman AD, Rabe KG, Boddicker NJ, et al. Progression and survival of MBL: a screening study of 10,139 individuals. Blood 2022;140:1702\u20139.","journal-title":"Blood"},{"key":"1341_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14175","volume":"8","author":"PJ Law","year":"2017","unstructured":"Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, et al. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nat Commun 2017;8:14175.","journal-title":"Nat Commun"},{"key":"1341_CR6","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1182\/blood-2017-11-814608","volume":"131","author":"G Kleinstern","year":"2018","unstructured":"Kleinstern G, Camp NJ, Goldin LR, Vachon CM, Vajdic CM, de Sanjose S, et al. Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 2018;131:2541\u201351.","journal-title":"Blood"},{"key":"1341_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41375-021-01344-9","volume":"36","author":"G Kleinstern","year":"2022","unstructured":"Kleinstern G, Weinberg JB, Parikh SA, Braggio E, Achenbach SJ, Robinson DP, et al. Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. Leukemia 2022;36:119\u201325.","journal-title":"Leukemia"},{"key":"1341_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562:203\u20139.","journal-title":"Nature"},{"key":"1341_CR9","doi-asserted-by":"crossref","unstructured":"Boutin NT, Schecter SB, Perez EF, Tchamitchian NS, Cerretani XR, Gainer VS, et al. The evolution of a large biobank at Mass General Brigham. J Pers Med. 2022;12:1323.","DOI":"10.3390\/jpm12081323"},{"key":"1341_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41586-018-0321-x","volume":"559","author":"PR Loh","year":"2018","unstructured":"Loh PR, Genovese G, Handsaker RE, Finucane HK, Reshef YA, Palamara PF, et al. Insights into clonal haematopoiesis from 8342 mosaic chromosomal alterations. Nature 2018;559:350\u20135.","journal-title":"Nature"},{"key":"1341_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-020-2426-2","volume":"584","author":"C Terao","year":"2020","unstructured":"Terao C, Suzuki A, Momozawa Y, Akiyama M, Ishigaki K, Yamamoto K, et al. Chromosomal alterations among age-related haematopoietic clones in Japan. Nature 2020;584:130\u20135.","journal-title":"Nature"},{"key":"1341_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41586-024-07533-7","volume":"631","author":"A Liu","year":"2024","unstructured":"Liu A, Genovese G, Zhao Y, Pirinen M, Zekavat SM, Kentistou KA, et al. Genetic drivers and cellular selection of female mosaic X chromosome loss. Nature 2024;631:134\u201341.","journal-title":"Nature"},{"key":"1341_CR13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41591-021-01371-0","volume":"27","author":"SM Zekavat","year":"2021","unstructured":"Zekavat SM, Lin SH, Bick AG, Liu A, Paruchuri K, Wang C, et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat Med 2021;27:1012\u201324.","journal-title":"Nat Med"},{"key":"1341_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01175-8","volume":"14","author":"A Sekar","year":"2024","unstructured":"Sekar A, Griffin R, Parikh SA, Genovese G, Robinson DP, Norman AD, et al. Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL). Blood Cancer J 2024;14:193.","journal-title":"Blood Cancer J"},{"key":"1341_CR15","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/s41375-022-01514-3","volume":"36","author":"NJ Boddicker","year":"2022","unstructured":"Boddicker NJ, Achenbach SJ, Parikh SA, Kleinstern G, Braggio E, Norman AD, et al. Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. Leukemia 2022;36:1404\u20137.","journal-title":"Leukemia"},{"key":"1341_CR16","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S2352-3026(16)30192-2","volume":"4","author":"AC Rawstron","year":"2017","unstructured":"Rawstron AC, Ssemaganda A, de Tute R, Doughty C, Newton D, Vardi A, et al. Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study. Lancet Haematol 2017;4:e334\u2013e40.","journal-title":"Lancet Haematol"},{"key":"1341_CR17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.17857","volume":"196","author":"FJ Vojdeman","year":"2022","unstructured":"Vojdeman FJ, Helby J, Pedersen LB, Brieghel C, Andersen MA, Nordestgaard BG, et al. Chronic lymphocytic leukaemia clones are detectable decades before diagnosis. Br J Haematol 2022;196:784\u20137.","journal-title":"Br J Haematol"},{"key":"1341_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41375-020-0980-0","volume":"35","author":"MA Andersen","year":"2021","unstructured":"Andersen MA, Rostgaard K, Niemann CU, Hjalgrim H. Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study. Leukemia 2021;35:747\u201351.","journal-title":"Leukemia"},{"key":"1341_CR19","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1182\/blood.2021012890","volume":"139","author":"PM Kolijn","year":"2022","unstructured":"Kolijn PM, Hosnijeh FS, Spath F, Hengeveld PJ, Agathangelidis A, Saleh M, et al. High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis. Blood 2022;139:1557\u201363.","journal-title":"Blood"},{"key":"1341_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3324\/haematol.2022.282542","volume":"109","author":"E Quinten","year":"2024","unstructured":"Quinten E, Sepulveda-Yanez JH, Koning MT, Eken JA, Pfeifer D, Nteleah V, et al. Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia. Haematologica 2024;109:824\u201334.","journal-title":"Haematologica"},{"key":"1341_CR21","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3324\/haematol.2020.247908","volume":"106","author":"A Agathangelidis","year":"2021","unstructured":"Agathangelidis A, Galigalidou C, Scarfo L, Moysiadis T, Rovida A, Gounari M, et al. Infrequent \u201cchronic lymphocytic leukemia-specific\u201d immunoglobulin stereotypes in aged individuals with or without low-count monoclonal B-cell lymphocytosis. Haematologica 2021;106:1178\u201381.","journal-title":"Haematologica"},{"key":"1341_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390804","volume":"43","author":"CE Ryan","year":"2023","unstructured":"Ryan CE, Davids MS. Practical management of Richter transformation in 2023 and beyond. Am Soc Clin Oncol Educ Book 2023;43:e390804.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1341_CR23","doi-asserted-by":"crossref","unstructured":"Parry EM, Ten Hacken E, Wu CJ. Richter syndrome: novel insights into the biology of transformation. Blood. 2023;142:11\u201322.","DOI":"10.1182\/blood.2022016502"},{"key":"1341_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","volume":"29","author":"EM Parry","year":"2023","unstructured":"Parry EM, Leshchiner I, Guieze R, Johnson C, Tausch E, Parikh SA, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med 2023;29:158\u201369.","journal-title":"Nat Med"},{"key":"1341_CR25","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","volume":"28","author":"F Nadeu","year":"2022","unstructured":"Nadeu F, Royo R, Massoni-Badosa R, Playa-Albinyana H, Garcia-Torre B, Duran-Ferrer M, et al. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. Nat Med 2022;28:1662\u201371.","journal-title":"Nat Med"},{"key":"1341_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg7915","volume":"16","author":"P Iyer","year":"2024","unstructured":"Iyer P, Zhang B, Liu T, Jin M, Hart K, Zhang J, et al. MGA deletion leads to Richter\u2019s transformation by modulating mitochondrial OXPHOS. Sci Transl Med 2024;16:eadg7915.","journal-title":"Sci Transl Med"},{"key":"1341_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2012.187","volume":"27","author":"J Moreira","year":"2013","unstructured":"Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia 2013;27:136\u201341.","journal-title":"Leukemia"},{"key":"1341_CR28","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3324\/haematol.2017.183954","volume":"103","author":"I Criado","year":"2018","unstructured":"Criado I, Rodriguez-Caballero A, Gutierrez ML, Pedreira CE, Alcoceba M, Nieto W, et al. Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. Haematologica 2018;103:1198\u2013208.","journal-title":"Haematologica"},{"key":"1341_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41375-020-0799-8","volume":"35","author":"TD Shanafelt","year":"2021","unstructured":"Shanafelt TD, Kay NE, Parikh SA, Achenbach SJ, Lesnick CE, Hanson CA, et al. Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). Leukemia 2021;35:239\u201344.","journal-title":"Leukemia"},{"key":"1341_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1182\/blood.2022017439","volume":"141","author":"G Oliva-Ariza","year":"2023","unstructured":"Oliva-Ariza G, Fuentes-Herrero B, Carbonell C, Lecrevisse Q, Perez-Pons A, Torres-Valle A, et al. High frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients. Blood 2023;141:309\u201314.","journal-title":"Blood"},{"key":"1341_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00754-x","volume":"12","author":"SA Parikh","year":"2022","unstructured":"Parikh SA, Achenbach SJ, Rabe KG, Norman AD, Boddicker NJ, Olson JE, et al. The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis. Blood Cancer J 2022;12:159.","journal-title":"Blood Cancer J"},{"key":"1341_CR32","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/ajh.27119","volume":"98","author":"G Oliva-Ariza","year":"2023","unstructured":"Oliva-Ariza G, Fuentes-Herrero B, Lecrevisse Q, Carbonell C, Perez-Pons A, Torres-Valle A, et al. Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis. Am J Hematol 2023;98:1909\u201322.","journal-title":"Am J Hematol"},{"key":"1341_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/leu.2015.235","volume":"30","author":"BM Solomon","year":"2016","unstructured":"Solomon BM, Chaffee KG, Moreira J, Schwager SM, Cerhan JR, Call TG, et al. Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia 2016;30:331\u20136.","journal-title":"Leukemia"},{"key":"1341_CR34","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"1341_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00532-1","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Achenbach SJ, Rabe KG, Shanafelt TD, Call TG, Ding W, et al. Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. Blood Cancer J 2021;11:140.","journal-title":"Blood Cancer J"},{"key":"1341_CR36","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood.2021011841","volume":"138","author":"LE Roeker","year":"2021","unstructured":"Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, et al. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood 2021;138:1768\u201373.","journal-title":"Blood"},{"key":"1341_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.105","volume":"6","author":"C da Cunha-Bang","year":"2016","unstructured":"da Cunha-Bang C, Simonsen J, Rostgaard K, Geisler C, Hjalgrim H, Niemann CU. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J 2016;6:e499.","journal-title":"Blood Cancer J"},{"key":"1341_CR38","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021;137:3165\u201373.","journal-title":"Blood"},{"key":"1341_CR39","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood.2022017814","volume":"140","author":"Y Shen","year":"2022","unstructured":"Shen Y, Freeman JA, Holland J, Naidu K, Solterbeck A, Van Bilsen N, et al. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. Blood 2022;140:2709\u201321.","journal-title":"Blood"},{"key":"1341_CR40","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","volume":"28","author":"LM Morton","year":"2010","unstructured":"Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, et al. Second malignancy risks after non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010;28:4935\u201344.","journal-title":"J Clin Oncol"},{"key":"1341_CR41","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/bjc.2013.381","volume":"109","author":"S Beiggi","year":"2013","unstructured":"Beiggi S, Johnston JB, Seftel MD, Pitz MW, Kumar R, Banerji V, et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer 2013;109:1287\u201390.","journal-title":"Br J Cancer"},{"key":"1341_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102307","volume":"65","author":"T Chatzikonstantinou","year":"2023","unstructured":"Chatzikonstantinou T, Scarfo L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, et al. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. EClinicalMedicine 2023;65:102307.","journal-title":"EClinicalMedicine"},{"key":"1341_CR43","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1200\/JCO.2012.43.4449","volume":"31","author":"BM Solomon","year":"2013","unstructured":"Solomon BM, Rabe KG, Slager SL, Brewer JD, Cerhan JR, Shanafelt TD. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol 2013;31:930\u20137.","journal-title":"J Clin Oncol"},{"key":"1341_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","volume":"139","author":"TD Shanafelt","year":"2007","unstructured":"Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 2007;139:255\u201364.","journal-title":"Br J Haematol"},{"key":"1341_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1046\/j.1365-2141.1996.d01-1796.x","volume":"94","author":"I Langenmayer","year":"1996","unstructured":"Langenmayer I, Nerl C, Knauf W, Dempster S, Hallek M, Adorf D, et al. Interferon-alpha 2b (IFN alpha) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: results of a randomized multicentre study. Br J Haematol 1996;94:362\u20139.","journal-title":"Br J Haematol"},{"key":"1341_CR46","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","volume":"338","author":"G Dighiero","year":"1998","unstructured":"Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on chronic lymphocytic leukemia. N. Engl J Med 1998;338:1506\u201314.","journal-title":"N. Engl J Med"},{"key":"1341_CR47","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1038\/leu.2017.246","volume":"31","author":"MA Hoechstetter","year":"2017","unstructured":"Hoechstetter MA, Busch R, Eichhorst B, Buhler A, Winkler D, Eckart MJ, et al. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia 2017;31:2833\u20137.","journal-title":"Leukemia"},{"key":"1341_CR48","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","volume":"34","author":"CD Herling","year":"2020","unstructured":"Herling CD, Cymbalista F, Gross-Ophoff-Muller C, Bahlo J, Robrecht S, Langerbeins P, et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia 2020;34:2038\u201350.","journal-title":"Leukemia"},{"key":"1341_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/blood.2021010845","volume":"139","author":"P Langerbeins","year":"2022","unstructured":"Langerbeins P, Zhang C, Robrecht S, Cramer P, Furstenau M, Al-Sawaf O, et al. The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia. Blood 2022;139:177\u201387.","journal-title":"Blood"},{"key":"1341_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/hon.3163_24","volume":"41","author":"P Langerbeins","year":"2023","unstructured":"Langerbeins P, Robrecht S, Nieper P, Cramer P, F\u00fcrstenau M, Al-Sawaf O, et al. Ibrutinib versus Placebo in patients with asymptomatic, treatment-na\u00efve early stage chronic lymphocytic leukemia (CLL): final results of the CLL12 trial. Hematol Oncol 2023;41:56\u20138.","journal-title":"Hematol Oncol"},{"key":"1341_CR51","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.24.00975","volume":"43","author":"P Langerbeins","year":"2025","unstructured":"Langerbeins P, Robrecht S, Nieper P, Cramer P, Furstenau M, Al-Sawaf O, et al. Ibrutinib in early-stage chronic lymphocytic leukemia: the randomized, placebo-controlled, double-blind, phase III CLL12 trial. J Clin Oncol 2025;43:392\u2013402.","journal-title":"J Clin Oncol"},{"key":"1341_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14225-8","volume":"11","author":"R Agius","year":"2020","unstructured":"Agius R, Brieghel C, Andersen MA, Pearson AT, Ledergerber B, Cozzi-Lepri A, et al. Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nat Commun 2020;11:363.","journal-title":"Nat Commun"},{"key":"1341_CR53","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41746-024-01132-6","volume":"7","author":"R Agius","year":"2024","unstructured":"Agius R, Riis-Jensen AC, Wimmer B, da Cunha-Bang C, Murray DD, Poulsen CB, et al. Deployment and validation of the CLL treatment infection model adjoined to an EHR system. NPJ Digit Med 2024;7:147.","journal-title":"NPJ Digit Med"},{"key":"1341_CR54","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 2020;183:347\u201362.e24.","journal-title":"Cell"},{"key":"1341_CR55","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 2024;403:632\u201344.","journal-title":"Lancet"},{"key":"1341_CR56","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","volume":"117","author":"D Bagnara","year":"2011","unstructured":"Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, Simone R, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011;117:5463\u201372.","journal-title":"Blood"},{"key":"1341_CR57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1182\/bloodadvances.2021006215","volume":"6","author":"C Bagacean","year":"2022","unstructured":"Bagacean C, Letestu R, Al-Nawakil C, Brichler S, Levy V, Sritharan N, et al. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. Blood Adv 2022;6:207\u201311.","journal-title":"Blood Adv"},{"key":"1341_CR58","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1182\/blood-2013-08-523001","volume":"123","author":"P Bachireddy","year":"2014","unstructured":"Bachireddy P, Hainz U, Rooney M, Pozdnyakova O, Aldridge J, Zhang W, et al. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 2014;123:1412\u201321.","journal-title":"Blood"},{"key":"1341_CR59","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1182\/blood.2021013926","volume":"139","author":"N Purroy","year":"2022","unstructured":"Purroy N, Tong YE, Lemvigh CK, Cieri N, Li S, Parry EM, et al. Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood 2022;139:2252\u20136.","journal-title":"Blood"},{"key":"1341_CR60","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-24-0022","volume":"5","author":"IM Ghobrial","year":"2024","unstructured":"Ghobrial IM, Gormley N, Kumar SK, Mateos MV, Bergsagel PL, Chesi M. et al. Round table discussion on optimal clinical trial design in precursor multiple myeloma. Blood Cancer Discov. 2024;5:146\u201352.","journal-title":"Blood Cancer Discov"},{"key":"1341_CR61","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1016\/S2352-3026(23)00086-8","volume":"10","author":"G Semenzato","year":"2023","unstructured":"Semenzato G, Ghobrial IM, Ghia P. Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity? Lancet Haematol 2023;10:e549\u2013e56.","journal-title":"Lancet Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01341-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01341-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01341-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:33:21Z","timestamp":1757453601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01341-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1341"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01341-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CER has received consulting fees from AstraZeneca and Genentech, and has received institutional research funding from BeiGene, Genentech, and Lilly. IEA has received consulting fees from AstraZeneca, BeiGene, and Lilly, and institutional research funding from BeiGene and Lilly. MA has received research funding from Gilead. AO has received institutional research support from BluePrint Medicines and institutional consultancy fees from Becton\/Dickinson Biosciences and BluePrint Medicines; he has also been a speaker for Amgen, Becton\/Dickinson Biosciences and AstraZeneca. AWL has received research funding from Roche-Genentech and Janssen. PL has received honoraria and personal fees from AbbVie, AstraZeneca, BeiGene, Janssen and has received research funding from Janssen. DMS has received consulting fees from Abbvie, AstraZeneca, Beigene, Genentech, Janssen, and Pharmacyclics, and has received institutional research funding from Abbvie, AstraZeneca, Beigene, BMS, and Novartis. CUN has received research funding and\/or consultancy fees from Abbvie, AstraZeneca, Janssen, BeiGene, Genmab, Octapharma, Takeda, CSL Behring, MSD, Lilly. SR has received research fundings from Bristol Myers Squibb. KS has received research support from AbbVie, AstraZeneca, Janssen, Lilly and Novartis. TS has received research support from AbbVie, Genentech, and Pharmacyclics. PG has received research funding from AbbVie, AstraZeneca, BeiGene, BMS, Janssen, Lilly and MSD and has received honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Galapagos, Janssen, MSD, Roche. JO has received consulting fees from AstraZeneca, BeiGene, Eisai, Genmab and Incyte and has received research funding from AstraZeneca, BeiGene and Genmab. MSD has received consulting fees from AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Genentech, Genmab, Janssen, Merck, MEI Pharma, Nuvalent, and Schr\u04e7dinger; has received institutional research funding from Ascentage Pharma, MEI Pharma, and Novartis, and receives royalties from Up-To-Date. AS, AR, JA, IMS, EMP, DPC, HV, SP, and SLS declare no relevant disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}